These data verify the previous reports that anti-tumour effect of the TGF-β antagonism mainly depends on CD8+ T cells (Donkor et al, 2011; Gorelik & Flavell, 2001; Nam et al, 2008; Zhang et al, 2005). The gene discussed is CD8A; the disease is neoplasm.